InfuSystem (NYSE:INFU) vs. PolyPid (NASDAQ:PYPD) Head-To-Head Survey

InfuSystem (NYSE:INFU) and PolyPid (NASDAQ:PYPD) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, earnings, dividends, profitability, analyst recommendations, valuation and risk.

Profitability

This table compares InfuSystem and PolyPid’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
InfuSystem	1.12%	2.78%	1.41%
PolyPid	N/A	-1,219.71%	-134.48%

Volatility & Risk

InfuSystem has a beta of 1.53, indicating that its share price is 53% more volatile than the S&P 500. Comparatively, PolyPid has a beta of 1.32, indicating that its share price is 32% more volatile than the S&P 500.

Institutional & Insider Ownership

71.1% of InfuSystem shares are owned by institutional investors. Comparatively, 26.5% of PolyPid shares are owned by institutional investors. 10.2% of InfuSystem shares are owned by company insiders. Comparatively, 24.7% of PolyPid shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of current recommendations for InfuSystem and PolyPid, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InfuSystem	0	0	0	2	4.00
PolyPid	0	0	2	0	3.00

InfuSystem presently has a consensus target price of $13.00, suggesting a potential upside of 72.41%. PolyPid has a consensus target price of $10.50, suggesting a potential upside of 238.71%. Given PolyPid’s higher possible upside, analysts plainly believe PolyPid is more favorable than InfuSystem.

Valuation and Earnings

This table compares InfuSystem and PolyPid”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InfuSystem	$132.78 million	1.21	$870,000.00	$0.06	125.67
PolyPid	N/A	N/A	-$23.86 million	($7.81)	-0.40

InfuSystem has higher revenue and earnings than PolyPid. PolyPid is trading at a lower price-to-earnings ratio than InfuSystem, indicating that it is currently the more affordable of the two stocks.

Summary

InfuSystem beats PolyPid on 11 of the 14 factors compared between the two stocks.

About InfuSystem

InfuSystem Holdings, Inc., through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states. The company also sells, rents, and leases new and pre-owned pole-mounted and ambulatory infusion pumps, and other durable medical equipment; sells treatment-related consumables; and provides biomedical recertification, maintenance, and repair services for oncology practices, as well as other healthcare site settings comprising hospitals, home care and home infusion providers, skilled nursing and acute care facilities, pain centers, and others. In addition, it offers local and field-based customer support, as well as operates pump service and repair centers. The company was incorporated in 2005 and is headquartered in Rochester Hills, Michigan.

About PolyPid

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. It is also developing OncoPLEX, for the treatment of intra-tumoral cancer. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.